Gateway Wealth Partners LLC Has $1.22 Million Stock Holdings in Pfizer Inc. $PFE

Gateway Wealth Partners LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 333.4% during the 1st quarter, Holdings Channel reports. The firm owned 43,591 shares of the biopharmaceutical company’s stock after purchasing an additional 33,532 shares during the quarter. Gateway Wealth Partners LLC’s holdings in Pfizer were worth $1,224,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PFE. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank lifted its position in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the period. Sei Investments Co. lifted its position in shares of Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC boosted its stake in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 2.3%

Shares of Pfizer stock opened at $25.25 on Wednesday. The company has a market capitalization of $143.88 billion, a P/E ratio of 19.27 and a beta of 0.35. The stock has a fifty day simple moving average of $25.09 and a 200 day simple moving average of $26.17. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is 131.30%.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. JPMorgan Chase & Co. decreased their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Citigroup increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. UBS Group reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts expect Pfizer to beat second-quarter earnings estimates, supported by favorable earnings expectations and improving revenue trends. The prospect of another earnings surprise may be encouraging investors ahead of the report. Pfizer Expected to Beat Earnings Estimates
• Positive Sentiment: Pfizer completed a Phase 1 study evaluating the tablet formulation of ibuzatrelvir, an antiviral candidate. While early-stage data do not establish commercial success, the update represents progress in Pfizer’s pipeline and could support longer-term growth expectations. Pfizer Fine Tunes Ibuzatrelvir Tablet
• Positive Sentiment: The FDA’s priority review of TALZENNA in combination with XTANDI for an earlier prostate-cancer setting could expand Pfizer’s oncology franchise. Investors may view the opportunity as a potential offset to declining legacy and COVID-related products. FDA Priority Review of TALZENNA
• Positive Sentiment: Several market commentaries highlighted Pfizer’s discounted valuation and argued that its patent-cliff concerns may already be reflected in the share price. This value-investing narrative likely contributed to buying interest. Pfizer Valuation and Patent Cliff Analysis

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.